Radiofrequency Versus Cryoballoon 180‐Day Mortality Risk After Atrial Fibrillation Ablation: An 8‐Year Analysis
Pacing and Clinical Electrophysiology · 2025
DOI: 10.1111/pace.15164 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pacing and Clinical Electrophysiology, 2025. Verfasst von Michal Orczykowski und 14 weiteren Autor:innen. Beteiligte Einrichtung: Arrhythmia Center, National Institute of Cardiology, Warsaw, Poland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Catheter Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Introduction
Catheter ablation (CA) is a preferred treatment for atrial fibrillation (AF), often outperforming antiarrhythmic medications in maintaining sinus rhythm and managing symptoms. One of the most important features of any treatment method, alongside its effectiveness, is its safety.
Methods
This study evaluates 180‐day all‐cause mortality rates post‐ablation using data from the National Health Fund in Poland (NHF‐P), encompassing over 99% of AF CAs and 100% of deaths in Poland from 2012 to 2019.
Results
Our analysis, which included 31,214 ablations on 26,767 patients (34.8% female), compared cryoballoon and radiofrequency (RF) ablation techniques and assessed mortality rates and risk factors. The study revealed a 180‐day mortality rate of 0.56%, with the highest rate observed in patients over 80 years old (2.67%) and the lowest in those aged 18–34 years (0.29%). Mortality did not significantly differ between cryoballoon (0.48%) and RF ablation (0.65%; p = 0.072). The risk of mortality did not differ between patients undergoing a first‐time ablation and those having subsequent procedures ( p = 0.90, OR 0.92). Significant risk factors for increased mortality included male sex, kidney disease, heart failure, diabetes, prior myocardial infarction, and a history of malignancy.
Conclusion
The 180‐day mortality rate after AF ablation procedure reached 0.56%, with no significant difference between cryoballoon and RF ablation. Further research, including matched control groups and extended follow‐up periods, is essential to better understand the benefits and risks of CA for AF, particularly in the oldest patient groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Arrhythmia Center, National Institute of Cardiology, Warsaw, Poland.
- Staten Island University Hospital, Staten Island, New York, USA.
- Faculty of Computer Science, Bialystok University of Technology, Bialystok, Poland.
- Department of Cardiology, Medical University of Lublin, Lublin, Poland.
- Medicover Hospital, Warsaw, Poland.
ORCID-Profile: Maciej Bak
Zitieren
APA
Orczykowski, M., Kowalski, M., Bak, M., Jargielo, A., Machaj, F., Swierczewski, M., Guzek, K., Topczewska, M., Urbanek, P., Robert, B., Glowniak, A., Derejko, P., Sterlinski, M., Bilinska, M., & Szumowski, L. (2025). Radiofrequency Versus Cryoballoon 180‐Day Mortality Risk After Atrial Fibrillation Ablation: An 8‐Year Analysis. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15164
Vancouver
Orczykowski M, Kowalski M, Bak M, Jargielo A, Machaj F, Swierczewski M, et al. Radiofrequency Versus Cryoballoon 180‐Day Mortality Risk After Atrial Fibrillation Ablation: An 8‐Year Analysis. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.15164
BibTeX
@article{Orczykowski2025,
author = {Orczykowski, Michal and Kowalski, Marcin and Bak, Maciej and Jargielo, Anna and Machaj, Filip and Swierczewski, Michal and Guzek, Krystyna and Topczewska, Magdalena and Urbanek, Piotr and Robert, Bodalski and Glowniak, Andrzej and Derejko, Pawel and Sterlinski, Maciej and Bilinska, Maria and Szumowski, Lukasz},
title = {Radiofrequency Versus Cryoballoon 180‐Day Mortality Risk After Atrial Fibrillation Ablation: An 8‐Year Analysis},
journal = {Pacing and Clinical Electrophysiology},
year = {2025},
doi = {10.1111/pace.15164}
}
EUVIMED